CAMBRIDGE, Mass., April 27, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that Editas scientists will present data from its cancer, hematology, ophthalmology and neuromuscular disease programs at the 19th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). In addition, Editas scientists will present updated data from the Company’s research program to develop therapies for the retinal degenerative disease LCA10 at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). The ASGCT meeting will take place May 4-7 in Washington D.C., and the ARVO meeting will take place May 1-5 in Seattle, WA.
“The data to be presented at ASGCT and ARVO will show the broad promise of Editas’ pipeline and the productivity of our genome editing platform,” said Katrine S. Bosley, President and Chief Executive Officer of Editas Medicine. “We are committed to translating genome editing science into important medicines for patients in the years ahead.”
Following is a schedule of the Company’s presentations at ASGCT, including links to the abstracts:
Oral Presentation:
CRISPR/Cas9 Mediates Highly Efficient Gene Editing in Long-Term Engrafting Human Hematopoietic Stem/Progenitor Cells
Date/Time: Saturday, May 7, 10:15 a.m.-12:15 p.m.
Location: Washington 1-2
Session Info: Targeted Genome Editing: Methods and Technology
Poster Presentations:
Therapeutic Correction of an LCA-Causing Splice Defect in the CEP290 Gene by CRISPR/Cas-Mediated Genome Editing
Date/Time: Wednesday, May 4, 5:30-7:30 p.m.
Location: Exhibit Hall C & B South
Session Info: Targeted Genome Editing I
Screening S. Aureus CRISPR-Cas9 paired-guide RNAs for efficient targeted deletion in Duchenne muscular dystrophy
Date/Time: Thursday, May 5, 6-8 p.m.
Location: Exhibit Hall C & B South
Session Info: Targeted Genome Editing II
Successful Generation of CAR+PD-1- Primary T Cells Using Cas9-Mediated Genome Editing
Date/Time: Friday, May 6, 6-8 p.m.
Location: Exhibit Hall C & B South
Session Info: Targeted Genome Editing III
DNA Ends Matter: The Impact of Using CRISPR/Cas9 Variants on DNA Repair Pathway Choices and Editing Profiles at the HBB Locus
Date/Time: Friday, May 6, 6-8 p.m.
Location: Exhibit Hall C & B South
Session Info: Targeted Genome Editing III
Following is a schedule of the Company’s poster presentation at ARVO, including a link to the abstract:
Therapeutic Correction of an LCA-Causing Splice Defect in the CEP290 Gene by CRISPR/Cas-Mediated Genome Editing
Date/Time: Sunday, May 1, 3:15-5 p.m.
Location: Exhibit/Poster Hall C0001-C0042
Session Info: Poster Session – Biochemistry/Molecular Biology: Gene editing and therapies
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically defined diseases by correcting their disease-causing genes. The Company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
Forward Looking Statements
This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words ‘‘anticipate,'' ‘‘believe,'' ‘‘continue,'' ‘‘could,'' ‘‘estimate,'' ‘‘expect,'' ‘‘intend,'' ‘‘may,'' ‘‘plan,'' ‘‘potential,'' ‘‘predict,'' ‘‘project,'' ‘‘target,'' ‘‘should,'' ‘‘would,'' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of the Company's product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption "Risk Factors" included in the Company's Annual Report on Form 10-K, which is on file with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.